HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Biotechnology
mo:re
Seed Round in 2025
Mo:re specializes in developing a three-dimensional cell robotic platform designed to automate medical research. Its platform aims to standardize cell culture workflows for drug development, enabling researchers to scale up experiments while maintaining traceability and quality.
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Akribion Genomics
Seed Round in 2025
Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.
Variolytics
Venture Round in 2025
Variolytics is a developer of advanced measurement technologies, specializing in mass spectrometry for environmental applications, particularly in sewage treatment plants. The company focuses on measuring all gas components, including greenhouse gases, within aeration tanks. Variolytics offers a range of products including measuring devices, sensor technologies, and monitoring systems that facilitate accurate data collection and process integration. In addition to its innovative measurement solutions, the company conducts process engineering research and development, providing expert advice and implementation services to help businesses optimize their industrial processes. By delivering insights into process dynamics, Variolytics enables companies to make informed decisions and enhance operational efficiency.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Refoxy Pharma
Seed Round in 2024
Refoxy Pharma develops therapeutic medicines intended to treat age-related diseases and promote healthy longevity. It researches proteins that regulate multiple genes involved in stress resistance and metabolism and develops novel modulators of a central stress response pathway to influence aging through genetics, with the aim of extending the years of healthy living for patients.
SRTD Biotech
Seed Round in 2024
SRTD Biotech is a biotechnology company specializing in RNA-based therapies. It develops a pro-drug platform targeting various diseases, including cancer, viral infections, and genetic disorders. The company's approach involves selectively delivering RNAs to patients using techniques such as RNAi interference, mRNA, and fusogenic liposomes for organ-specific targeting, aiming to treat previously incurable conditions.
Zymofix
Seed Round in 2024
Zymofix facilitates sustainable and circular agriculture by developing creative, effective, and commercially feasible microbial products that reduce farmers' reliance on agrochemicals while maintaining high productivity.
Nuuron
Seed Round in 2024
Nuuron is a neurotechnology company specializing in the development of a non-invasive, photonic neurostimulation device called the Memory-Pacemaker. This device is designed to help Alzheimer's patients store and retrieve memories by activating the memory center in the brain via the retina, acting as a computer-brain interface. The company's proprietary platform algorithms generate ultra-high frequency, digital photonic stimuli to achieve this.
Aignostics
Series B in 2024
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
BIOVOX
Seed Round in 2024
BIOVOX develops sustainable plastic materials tailored for healthcare applications. Their compounds are renewable, degradable, recyclable, and offer rigidity, surface hardness, and transparency, enabling medical manufacturers to reduce environmental impact while maintaining high safety standards.
IRUBIS
Seed Round in 2024
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
HepaRegenix
Series C in 2024
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
SciRhom
Series A in 2024
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
Cultimate Foods
Seed Round in 2024
Cultimate Foods is a cellular agriculture company focused on cultivated fat for hybrid alternative-meat products. It develops cell-cultured fat that mimics the structure of animal fat tissue, using a three-dimensional cultivation approach to create structured fat ingredients and lower production costs. The company also pursues cell-engineered adipose tissue to enable meat alternatives that combine cultivated fat biomass with other ingredients, delivering the flavor and texture of meat while supporting sustainability.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
FarmInsect
Series A in 2023
FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.
traceless materials
Series A in 2023
traceless materials is offering a holistically sustainable alternative to plastics and bioplastics. With our first-of-a-kind biomaterial it’s our mission to contribute to solving global plastic pollution.
Our innovative technology filed for patent allows to use food production residues to produce materials that are compostable under natural composting conditions. While bio-based, our materials don’t compete with food nor cause land-use-change, don’t need hazardous additives or solvents and have up to 95% lower CO2 emissions. Our materials are neither chemically modified nor synthetically polymerized, therefore they will not fall under the EU Single Use Plastic Directive.
Follow us on our journey, and become a part of the solution, not the pollution!
Bind-X
Series B in 2023
Bind-X is a biotechnology company focused on enhancing the sustainability of various industries through innovative applications. The company specializes in the development of microbiologically induced bio-cement, which utilizes a bio-geochemical process to facilitate calcium carbonate precipitation within soil. This technology enables clients to transform sand into bricks, providing an environmentally friendly and cost-effective solution for dust control and pollution management. By optimizing biotechnological processes, Bind-X aims to improve both the sustainability and profitability of its clients' operations.
DNTOX
Seed Round in 2023
DNTOX operates a bioanalytical testing laboratory specializing in animal-free screening of chemicals. Its in vitro testing battery uses human cell models for high-content, medium-throughput chemical screening, supported by proprietary AI software. The company assists clients in identifying safe lead structures during substance development and assessing safety during approval processes.
smartbax
Seed Round in 2023
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Dualyx
Series A in 2023
Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.
Phialogics
Pre Seed Round in 2023
Phialogics is a biotechnology company focused on developing innovative biologics to regulate the immune response in both acute and chronic inflammation. Its platform enables the creation of engineered antibodies and cell-type-specific immune checkpoint activators, targeting autoimmune diseases such as lupus, type 1 diabetes, and rheumatoid arthritis.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.
Agriportance
Seed Round in 2022
Agriportance is a software-as-a-service company operating in Europe's renewable energy sector. Founded in 2020, it specializes in software for sustainability certification under REDcert-EU and ISCC-EU, allowing users to generate mass and greenhouse gas balances online. The platform connects biomethane producers with mineral oil companies and monitors sustainability certification and the buying and selling of biomethane using greenhouse gas accounting, enabling a carbon footprint aligned with the Renewable Energy Directive. The company plans to expand into trading renewable energy quotas and to strengthen its European market presence, following seed funding in December 2022 to enhance its digital capabilities.
Variolytics
Seed Round in 2022
Variolytics is a developer of advanced measurement technologies, specializing in mass spectrometry for environmental applications, particularly in sewage treatment plants. The company focuses on measuring all gas components, including greenhouse gases, within aeration tanks. Variolytics offers a range of products including measuring devices, sensor technologies, and monitoring systems that facilitate accurate data collection and process integration. In addition to its innovative measurement solutions, the company conducts process engineering research and development, providing expert advice and implementation services to help businesses optimize their industrial processes. By delivering insights into process dynamics, Variolytics enables companies to make informed decisions and enhance operational efficiency.
FundaMental Pharma
Seed Round in 2022
FundaMental Pharma is a neuroscience company developing novel drugs targeting neurodegeneration. Its portfolio focuses on preclinical stage therapies designed to uncouple the physiological function of glutamate-gated NMDA receptors from their toxic effects, aiming to stop neurodegeneration and improve brain health.
Resolve BioSciences
Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
IRUBIS
Seed Round in 2022
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
Kupando
Series A in 2022
Kupando is a biopharmaceutical company focused on developing immunostimulatory agents targeting toll-like receptors. Its mission is to create affordable immunotherapy options for cancer patients and prevent infectious diseases.
Aignostics
Series A in 2022
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
FaCellitate
Seed Round in 2022
FaCellitate is a developer of innovative biomedical technology focused on enhancing cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The company specializes in creating polymeric platforms that provide chemically defined, animal- and xeno-free cell culture coatings. These advanced coatings facilitate improved cellular interactions, thereby significantly enhancing cell culture practices in biological research. By offering smart lab surfaces, FaCellitate enables researchers to conduct more effective experiments, contributing to advancements in various fields of biomedical research.
Invasight
Seed Round in 2022
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Ebenbuild
Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Ceregate
Series A in 2022
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.
Nebula Biocides
Seed Round in 2021
Nebula Biocides is a company that specializes in the development of innovative disinfection solutions aimed at effectively combating infection. The company focuses on creating application-oriented products that target persistent bacterial spores and resilient viruses, ensuring comprehensive protection for users in various environments. Nebula Biocides offers a range of smart disinfection devices designed to deliver reliable and efficient disinfection, making them suitable for diverse applications. Through its commitment to effective infection control, Nebula Biocides strives to enhance public health and safety by providing advanced disinfection technologies.
Computomics
Venture Round in 2021
Founded in 2012, Computomics specializes in molecular data analysis for crop biotechnology companies and scientists. It offers services such as genome assembly, transcriptome studies, functional annotation, reference-free genotyping, DNA methylation analysis, metagenomic analysis, genomic selection, and crop genome consulting.
Abalos Therapeutics
Series A in 2021
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
FarmInsect
Seed Round in 2021
FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.
Alentis Therapeutics
Series B in 2021
Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.
traceless materials
Seed Round in 2021
traceless materials is offering a holistically sustainable alternative to plastics and bioplastics. With our first-of-a-kind biomaterial it’s our mission to contribute to solving global plastic pollution.
Our innovative technology filed for patent allows to use food production residues to produce materials that are compostable under natural composting conditions. While bio-based, our materials don’t compete with food nor cause land-use-change, don’t need hazardous additives or solvents and have up to 95% lower CO2 emissions. Our materials are neither chemically modified nor synthetically polymerized, therefore they will not fall under the EU Single Use Plastic Directive.
Follow us on our journey, and become a part of the solution, not the pollution!
ActiTrexx
Series A in 2021
ActiTrexx is a biotechnology company developing cellular therapies to mitigate inflammatory reactions in conditions such as graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune disorders. Their flagship product, ATREGA, aims to enhance survival rates for transplanted patients.
GeneQuine Biotherapeutics
Series A in 2021
Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.
Lignopure
Seed Round in 2021
Lignopure is a manufacturer of naturally degradable biopolymers derived from non‑food lignin sources. Using proprietary technology, it converts raw lignin into tailored, non‑cytotoxic biopolymers that can replace environmentally and health‑harmful chemicals in material science. The company supplies customized lignin for cosmetics, pharmaceuticals, and food supplements, and develops biobased prototypes such as insulating materials, polyurethane foams, aerogels, and 3D‑printing filaments. Its protected technology delivers lignin with unique safety and functional properties, positioning Lignopure as a leading provider of sustainable, lignin‑based alternatives.
Resolve BioSciences
Series A in 2020
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
Synendos Therapeutics
Series A in 2020
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
Ceregate
Series A in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
Aignostics
Seed Round in 2020
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Atriva Therapeutics
Debt Financing in 2020
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
stimOS
Series A in 2020
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
Scipio Bioscience
Series A in 2020
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
Ceregate
Venture Round in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Verovaccines
Seed Round in 2019
VEROVACCiNES GmbH is a biopharmaceutical company based in Halle, Germany, founded in 2017 as a spin-off from the Martin Luther University Halle-Wittenberg. The company specializes in developing innovative vaccine solutions to protect animals from infectious diseases, utilizing a unique yeast-based technology to create subunit marker vaccines. This approach has been validated through proof-of-concept studies demonstrating protection across various animal species against several viral diseases. VEROVACCiNES has acquired intellectual property, branding, and expertise from a previous project funded by the BMBF GO-Bio program and is eligible for additional funding. The company actively collaborates with veterinary pharmaceutical firms, universities, and research institutions to enhance its vaccine development efforts.
Abalos Therapeutics
Series A in 2019
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Vacis
Venture Round in 2019
Vacis specializes in tissue engineering technology for creating body-own blood vessels. Its platform induces the body to form functional blood vessels, offering novel therapeutic options and reducing complications associated with prosthetic vascular grafts.
Tacalyx
Seed Round in 2019
Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.
Belyntic
Seed Round in 2019
Belyntic is a biotechnology company focused on developing innovative vaccines aimed at preventing viral diseases, bacterial infections, and cancer. The company has created a cutting-edge platform that utilizes self-adjuvant synthetic long peptides to effectively induce cellular immunity. By offering ready-to-use research kit packages and engineered vaccines, Belyntic activates T-cell immune responses, providing significant potential for advancing protective measures against various health threats. Additionally, the company integrates artificial intelligence to enhance its vaccine development, allowing for the incorporation of pathogen-specific epitopes into a self-adjuvant nano vaccine structure. This approach facilitates research, development, and production of novel peptide therapeutics, contributing to healthier lives.
Pantherna Therapeutics
Seed Round in 2019
Pantherna Therapeutics GmbH is a biopharmaceutical company based in Hennigsdorf, Germany, founded in 2017. The company specializes in developing innovative mRNA therapeutics aimed at treating acute respiratory distress syndrome (ARDS) and vascular diseases. Pantherna Therapeutics utilizes a unique technology platform based on advanced nanoparticles that facilitate the delivery and expression of therapeutic mRNA drugs specifically in the endothelium. This approach aims to prevent the formation of edema and lung tissue injury associated with ARDS while also enabling the restoration of endothelial cell function.
DyNAbind
Seed Round in 2019
Founded in 2015 and based in Dresden, Germany, DyNAbind develops regenerable biosensor drug discovery technologies. It offers DNA-encoded chemical library synthesis, selection, and decoding services, providing insights into target drugability and SAR analysis.
miRdetect
Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.
Alentis Therapeutics
Series A in 2019
Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Cytena
Series A in 2019
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
Plasmion
Seed Round in 2019
Plasmion specializes in developing ionization devices for scientific and industrial applications. Its flagship product, the SICRIT SC-20X ionization set, is used across various sectors such as quality control, food safety, medical diagnosis, and emission monitoring. The company serves customers globally through its network of sales partners.
4Gene
Seed Round in 2019
4Gene GmbH, based in Langenpreising, Germany, specializes in the development and production of natural, biotechnologically engineered flavor and fragrance precursors. Established in 2018, the company focuses on creating activatable products marketed as FLAVOR-ON-DEMAND, catering to a diverse range of sectors including food, cosmetics, pharmaceuticals, and industrial applications. 4Gene's innovative platform delivers non-volatile, chemically stable, and water-soluble solutions that activate when required, thereby enhancing user experiences across its global customer base in the flavor and fragrance industry.
Atriva Therapeutics
Series A in 2019
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
Preomics
Series A in 2018
PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.
denovoMATRIX
Seed Round in 2018
Founded in 2018, denovoMATRIX develops biomimetic coatings for stem cell culture. Its products include screenMATRIX, which enhances cell adhesion and differentiation, and myMATRIX, a custom-coated tissue cultureware for serum-free media. These are used in stem cell research, tissue models, and cell-based therapies.
Amal Therapeutics
Series B in 2018
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
OMEICOS Therapeutics
Series C in 2018
OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.
Adivo
Seed Round in 2018
Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
Amal Therapeutics
Series B in 2017
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
stimOS
Seed Round in 2017
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Signatope
Seed Round in 2017
Signatope develops protein biomarker assays leveraging mass spectrometry-based immunoassays to detect and quantify protein biomarkers across species. Founded in 2016 and based in Reutlingen, Germany, the company uses antibodies comprising epitopes of four amino acids as key reagents. Its assays support preclinical and clinical drug development by establishing quantitative measurements for the same protein across different species and isoforms, enabling clients in the pharmaceutical and chemical industries to obtain biotechnological analytics services.
NUMAFERM
Seed Round in 2017
NUMAFERM specializes in peptide production. Established in 2017, it offers services including feasibility studies, custom synthesis, peptide development, upscaling, and licensing. Its innovative manufacturing process significantly reduces production costs compared to traditional methods.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.
Atriva Therapeutics
Seed Round in 2017
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, specializing in the development of drugs for neurodegenerative diseases and hearing impairments. Founded in 2010 by Professor Hans Rommelspacher, the company has assembled a team of skilled scientists and executives, supported by a network of academic partners and strategic investors. AudioCure Pharma is located in a central area of Mitte, providing access to numerous high-tech companies and universities, including close ties with the Charité University. The company is focused on advancing its leading compound, AC102, which is in late-stage preclinical development for treating acute noise-induced hearing loss and has demonstrated preclinical proof of concept since 2016.
Immunic Therapeutics
Series A in 2016
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
Rigontec
Series A in 2016
Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.
CorTec
Series B in 2016
CorTec specializes in developing innovative medical devices for neuromodulation and brain-computer interfaces. Its flagship product is the CorTec Brain Interchange™ System, featuring flexible electrode arrays and a hermetically sealed electronics unit with custom microchip technology. The system enables permanent brain recordings and stimulation without the need for battery replacement surgery.
Thermosome
Seed Round in 2016
Thermosome GmbH is a biopharmaceutical company based in Planegg, Germany, specializing in the development of drug candidates utilizing a proprietary drug delivery technology. This platform, founded on research from the Max Planck Institute for Biophysical Chemistry, enables intravascular drug release, effectively targeting locally advanced solid tumors. Thermosome's lead product is a formulation of a chemotherapeutic compound currently in the final stages of pre-clinical development. The company's focus is on enhancing antitumor responses in cancer treatment, aiming to provide patients with more effective therapies that minimize side effects and expedite the initiation of treatment. Since its inception in late 2015, Thermosome has been dedicated to advancing innovative solutions in cancer care.
Amal Therapeutics
Series A in 2016
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
SeNostic Health GmbH
Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.